Managing Your Treatment Options

Because Fibrillary Glomerulonephritis (FGN) and Immunotactoid Glomerulopathy (ITG) are exceptionally rare, there is no single “gold standard” treatment that works for everyone. Instead, your medical team will build a highly individualized plan based on your biopsy results, your current kidney function, and whether an underlying blood condition was found ^[1].

Treatment generally falls into two categories: supportive care to protect your kidneys from further stress, and targeted therapy to try and stop the abnormal protein deposits at their source.

The Foundation: Supportive Care

Regardless of which specific disease you have, protecting your remaining kidney function is the first priority. This is often called “nephroprotection” ^[2].

When clinically appropriate, the most important tool in this category is RAAS blockade. This involves medications called ACE inhibitors (like lisinopril) or ARBs (like losartan) ^[1]. They are not for everyone and are contraindicated in acute kidney injury or hyperkalemia, and they should not be combined. These drugs do two vital things for FGN/ITG patients:

1. Lower Blood Pressure: High blood pressure puts physical “pressure” on the kidney filters, worsening the damage ^[3].
2. Reduce Proteinuria: These medications help “tighten” the filters so less protein leaks into your urine. In some cases, this alone has significantly slowed the disease ^[1][4].

Targeted Treatment for FGN

In FGN, the goal is sometimes to dampen the immune system to stop the production of the “fibrils” that clog the filters. However, the evidence for these treatments is mixed, and they are usually reserved for patients with high levels of protein in their urine or rapidly declining kidney function ^[5][6].

• Rituximab: This is sometimes considered for FGN. It is a biological therapy that targets the B-cells in your immune system ^[7]. While some studies show it can help stabilize kidney function and reduce protein levels, it is not a “cure.” In one small trial, about 27% of patients saw a partial improvement, but none saw their disease disappear completely ^[7]. It carries risks including infusion reactions, serious infections, Hepatitis B reactivation, and low immunoglobulins. Hepatitis B screening is required before starting.
• Steroids and Combinations: Sometimes, doctors use corticosteroids (like prednisone) alone or in combination with other drugs like cyclophosphamide ^[8][9]. These are potent drugs that reduce inflammation but carry more significant side effects.
• The “Scarring” Factor: If your biopsy shows a lot of old scarring (sclerosis), your doctor may advise against strong immune drugs. This is because these medications can only stop active inflammation—they cannot “fix” filters that have already turned into scar tissue ^[8][6].

Targeted Treatment for ITG: “Clone-Directed” Therapy

For ITG, the treatment strategy is usually more direct. Because ITG is so frequently linked to a specific “clone” of abnormal immune cells (like in CLL or MGRS), a common approach when a clone is found is to treat that specific clone ^[10][11].

This is called clone-directed therapy. If a blood disorder is found, your nephrologist will work closely with a hematologist (blood specialist) to use treatments like:

• Chemotherapy-like agents: Medications such as bortezomib or cyclophosphamide that target the abnormal cells ^[12].
• Targeted Biologicals: If you have CLL, drugs like ibrutinib may be used to treat both the leukemia and the kidney disease at the same time ^[13].
• MGRS Treatment: Even if you don’t have “cancer,” if an abnormal protein clone is found, treating the clone to protect the kidney is often the best way to save the kidneys ^[14][15].

What to Expect and Monitor

All treatments for FGN and ITG require close monitoring to balance the benefits against the risks.

• Side Effects: Rituximab can cause infusion reactions, fatigue, nasal congestion, or muscle cramps, as well as the infectious risks noted above ^[7]. Stronger immunosuppressants increase the risk of infections because they lower your body’s defenses, and have bone, metabolic, and bladder risks ^[9].
• Measuring Success: Your doctor will regularly check your eGFR (kidney function) and your UPCR (urine protein level) ^[7]. Remission definitions vary by study, but typically involve a specific reduction in proteinuria combined with stable kidney function ^[7][9].
• Relapse: These conditions can be stubborn. Even if you respond well to treatment, your doctor will continue to monitor you because the disease can sometimes return when the immune system recovers ^[16].